ERBB2 and cholangiocarcinoma: Therefore, this report presents the first real-world evidence of the efficacy and safety of Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate (ADC) composed of a humanized monoclonal anti-HER2 antibody, for the treatment of advanced cholangiocarcinoma and management of subsequent drug resistance.